Oura Acquires Counsel Health for $625 Million to Boost AI Care

Oura has agreed to purchase Counsel Health, an AI-native primary care provider, for $625 million. This deal follows the company's recent decision to delay its planned $2.2 billion IPO due to broader market instability. The Scale Report understands that this move is a strategic play to transition from passive biometric tracking to active medical intervention.

Integrating AI Into Personal Health

Counsel Health uses a combination of generative medical AI and licensed physicians to provide care. This service was already embedded into the Oura app starting this June. By bringing the startup in-house, the company intends to scale its offerings across acute, chronic, and preventative medical domains.

Leadership and Market Strategy

Muthu Alagappan, current chief executive officer of Counsel, will join the Oura leadership team as the chief clinical AI officer. Alongside him, the startup's 70-person staff will migrate to the parent company. Tom Hale, the chief executive officer of Oura, stated that this integration allows users to move from simply understanding their physiology to acting on specific health needs like lab results and prescriptions.

Why This Matters

This acquisition highlights a pivotal shift for hardware-centric health companies. As competition from wearable rivals like RingConn and Ultrahuman intensifies, firms are increasingly forced to move up the value chain toward recurring revenue models tied to clinical services. By turning biometric data into actionable care, Oura is attempting to build a defensive moat that raw step-counting or sleep-tracking devices cannot replicate.

Oura continues to see rapid growth, reporting $1.75 billion in revenue for fiscal year 2026, a 92% increase compared to the prior year. The company reached an $11 billion valuation last October following a significant late-stage funding round. Despite this financial momentum, the acquisition signals a clear pivot toward health-tech vertical integration.